Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Capital Expenditures (2016 - 2025)

OptimizeRx (OPRX) has disclosed Capital Expenditures for 14 consecutive years, with -$33000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 73.17% to -$33000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58000.0 through Dec 2025, down 48.21% year-over-year, with the annual reading at $58000.0 for FY2025, 48.21% down from the prior year.
  • Capital Expenditures hit -$33000.0 in Q4 2025 for OptimizeRx, down from $54000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $702000.0 in Q4 2023 to a low of -$123000.0 in Q4 2024.
  • Historically, Capital Expenditures has averaged $60894.1 across 5 years, with a median of $26927.5 in 2022.
  • Biggest five-year swings in Capital Expenditures: soared 7621.31% in 2021 and later crashed 117.52% in 2024.
  • Year by year, Capital Expenditures stood at $37757.0 in 2021, then skyrocketed by 161.92% to $98893.0 in 2022, then soared by 609.86% to $702000.0 in 2023, then plummeted by 117.52% to -$123000.0 in 2024, then skyrocketed by 73.17% to -$33000.0 in 2025.
  • Business Quant data shows Capital Expenditures for OPRX at -$33000.0 in Q4 2025, $54000.0 in Q3 2025, and $10000.0 in Q2 2025.